Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07628283

A Novel Rural Integrated Care and Early Prevention Model for Older Adults at High Risk of or Living With Stroke in China

This cluster randomized controlled trial aims to evaluate the effectiveness of a novel telemedicine-enabled integrated care model led by rural doctors in reducing cardiovascular and cerebrovascular events among elderly adults (≥65 years) at high risk of stroke in rural China. A total of 39 village clinics will be randomized to either the intervention group (digital health platform-supported integrated care) or the control group (enhanced usual care). The primary outcome is a composite of cardiovascular death, stroke, and hospitalization for heart failure or acute coronary syndrome at 36 months.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Stroke Brain Diseases Brain Ischemia Cardiovascular Diseases Central Nervous System Diseases Cerebral Hemorrhage Cerebrovascular Disorders Hemorrhage Hypertension Intracranial Hemorrhages Ischemic Attack, Transient Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Transient Ischemic Attack Vascular Diseases

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Jiangsu Province （Suqian）Hospital, Suqian, Jiangsu, China

Loading trial locations.

About this study

Stroke is the leading cause of death and disability in China, with a disproportionately higher burden in rural areas. This study proposes a "technology-enabled, vertically integrated, pathway-integrated, performance-incentivized" care model to address the gaps in rural stroke management. The intervention group will use a dedicated digital health platform (https://ricestroke.sqfh.org.cn:8421/gp/#/login) that provides clinical decision support, remote consultation with specialists, patient follow-up reminders, and performance feedback for rural doctors. The control group will receive enhanced usual care without the digital platform. The study will enroll 2510 participants and follow them for 36 months to assess the impact of the intervention on clinical outcomes, risk factor control, and medication adherence.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 65 years or older
  • Rural residents with household registration or long-term residence (≥6 months/year) in the study area
  • High risk of stroke as defined by the National Health Commission's "8+2" stroke risk screening tool: ≥3 risk factors OR history of stroke/TIA
  • Willing to receive long-term health management from the assigned village clinic
  • Written informed consent provided by the participant or their legal representative

Exclusion criteria

  • Severe dementia or psychiatric disorder that prevents completion of study follow-up and assessments
  • Life expectancy less than 1 year (e.g., advanced malignancy, end-stage renal disease)
  • Currently participating in another interventional clinical trial

Treatment and study plan

Enhanced Usual Stroke Care

Behavioral

Rural doctors provide monthly face-to-face care based on national guidelines, including symptom monitoring, blood pressure measurement, medication guidance, and patient education. Referrals to tertiary hospitals are made through conventional channels.

Digital Health Platform-Supported Integrated Stroke Management

Behavioral

Patient electronic health record management AI-powered clinical decision support for medication adjustment based on Chinese stroke guidelines Weekly remote video consultation with neurologists from tertiary hospitals Automated follow-up and medication adherence reminders Structured education and training for both rural doctors and patients

Primary outcomes

  1. Composite of Cardiovascular Death, Stroke, and Hospitalization for Heart Failure or Acute Coronary Syndrome at 36 Months

    Time frame: 36 months

    The primary composite endpoint includes: (1) cardiovascular death; (2) first occurrence of stroke (ischemic, hemorrhagic, or undetermined type); (3) hospitalization for worsening heart failure or acute coronary syndrome. All events will be adjudicated by an independent clinical events committee blinded to treatment assignment.

Secondary outcomes

  1. First Recurrent Stroke Event Rate at 36 Months

    Time frame: 36 months

    Time to first recurrent stroke (ischemic, hemorrhagic, or undetermined type) confirmed by CT/MRI imaging

  2. All-Cause Mortality at 36 Months

    Time frame: 36 months

    Death from any cause

  3. Cardiovascular-Specific Mortality at 36 Months

    Time frame: 36 months

    Death due to cardiovascular causes including sudden cardiac death, myocardial infarction, heart failure, and stroke

  4. Hospitalization for Heart Failure or Acute Coronary Syndrome at 36 Months

    Time frame: 36 months

    Number of participants hospitalized for worsening heart failure or acute coronary syndrome

  5. Major Bleeding Events (ISTH Criteria) at 36 Months

    Time frame: 36 months

    Number of participants experiencing major bleeding events as defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria

  6. Change in CHINA-PAR Score from Baseline to Month 12

    Time frame: Baseline, Month 12

    Change in 10-year ASCVD risk percentage as calculated by the CHINA-PAR risk prediction model in participants without prior stroke history Scale name: The output result is the 10-year ASCVD incidence risk percentage, in%, which is a continuous probability value.

    Theoretical range of values:

    Minimum value: 0%, representing no risk of ASCVD in the next 10 years; Maximum value: 100%, representing the inevitable occurrence of ASCVD in the next 10 years.

    The higher the score, the worse the result (higher risk). The scoring value directly corresponds to the probability of onset: the higher the value, the greater the probability of ASCVD events such as myocardial infarction, coronary heart disease death, and stroke occurring in the subject within the next 10 years, and the more severe the cardiovascular health risk; On the contrary, the lower the score, the lower the risk of onset and the better the cardiovascular prognosis.

Study contacts

Contact information is provided by the study sponsor or research team.

Liu Qianghui Director of Suqian Hospital, Jiangsu Provincial People's Hospi

CONTACT

[email protected]

15951598055

Sponsors and collaborators

Lead sponsor

Jiangsu Province (Suqian) Hospital

Other

Registry information

Official study title

A Prospective, Open-Label, Cluster Randomized Controlled Trial to Evaluate the Efficacy of a Rural Doctor-Led, Telemedicine-Supported Integrated Care Model for Reducing Cardiovascular and Cerebrovascular Events in Elderly Adults at High Risk of Stroke in China

Important dates

Study start
2026
Primary completion
2029
Study completion
2030
First posted
Jun 5, 2026
Registry last updated
Aug 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.